UBS initiated coverage on IDEXX Labs with a new price target
$IDXX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
UBS initiated coverage of IDEXX Labs with a rating of Neutral and set a new price target of $720.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2025 | $720.00 | Neutral | UBS |
| 8/5/2025 | $545.00 → $785.00 | Buy | BTIG Research |
| 7/1/2025 | $625.00 | Buy | Jefferies |
| 12/2/2024 | $500.00 | Outperform | Leerink Partners |
| 7/25/2024 | $580.00 | Buy | BTIG Research |
| 1/30/2024 | $525.00 | Overweight → Neutral | Piper Sandler |
| 12/7/2023 | $602.00 | Outperform | Exane BNP Paribas |
| 12/4/2023 | Neutral → Buy | Cleveland Research |
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Monday, November 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025. "We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Karen is a highly accomplished executive with deep B2B, SaaS software and AI experience gained through building and running software and technology companies at various lifecycle stages. We are confident that her extensive professional experience and skills will complement those of our other Board members and contribute to our Board's overal
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Jay Mazelsky, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 from 1:50 pm – 2:25 pm (ET). A live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will be available via the same link. About IDEXX Laboratories, Inc. IDEXX is a global leader in pet healthcare innovation. Our diagnostic an
UBS initiated coverage of IDEXX Labs with a rating of Neutral and set a new price target of $720.00
BTIG Research reiterated coverage of IDEXX Labs with a rating of Buy and set a new price target of $785.00 from $545.00 previously
Jefferies initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $625.00
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025. "We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Karen is a highly accomplished executive with deep B2B, SaaS software and AI experience gained through building and running software and technology companies at various lifecycle stages. We are confident that her extensive professional experience and skills will complement those of our other Board members and contribute to our Board's overal
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro
BRADENTON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ:FWRG) ("First Watch" or the "Company"), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Irene Chang Britt to its Board of Directors, effective immediately. Ms. Chang Britt is an experienced independent board director and former Fortune 500 C-suite executive, who currently serves on the boards of established businesses and start-up companies representing a variety of industries, including retail, CPG, e-commerce and lifestyle. "We are thrilled to welcome Irene to the Board of Directors of First Watch, and I'm confident that our company wil
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Monday, November 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen
Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic. Advances IDEXX's innovation agenda and continues strong global commercial execution, resulting in record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx™ placements. Delivers EPS of $3.63, an increase of 49% as reported, and 17% on a comparable basis, net of $0.56 EPS growth benefit from comparison to prior year period discrete litigation expense accrual, and including $0.07 benefit from a discrete tax reserve release. Increases 2025 revenue guidance to $4,205 million - $4,280 million, an increas
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)